KBI Biopharma Capabilities Update May 2026: Mammalian Cell Culture

Cell line development is no longer just a technical step — it's a strategic driver of biologics success. This presentation explores how KBI Biopharma's Celexis platform, built on over 20 years of continuous innovation, is accelerating the journey from DNA to patient across productivity, stability, and safety.

Key topics include KBI's shift from random to semi-targeted DNA integration — achieving 99% stable cell line rates — and the evolution to Transposase 2.0 with dual antibiotic selection for improved titers. The presentation also covers the B-Select platform for complex multi-chain molecules, an upcoming fully targeted integration system, and a first-of-its-kind retrovirus-like particle-low CHO cell line engineered for streamlined regulatory safety profiles.

The session closes with KBI's machine learning-driven codon optimization and early developability assessment tools, enabling clients to select the right molecule before committing to downstream development.